Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822564 | 0.88 | TGFBR1 (0.44) | TGFBR1MAPK14METAP2MTORCCR1 | |
| SCHEMBL29796486 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTORCCR1 | |
| SCHEMBL30156263 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL23390013 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTORCCR1 | |
| SCHEMBL25084996 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL30156054 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL25084697 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL30156056 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL25084652 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2MTOR | |
| SCHEMBL25084734 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885METAP2 1827/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885METAP2 1827/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885METAP2 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.